Clinical trial
Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.
NCT07833696 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Characteristics and Management of Patients With Severe Chronic Spontaneous and/or Inducible Urticaria Refractory to Optimized Omalizumab Treatment: A French Multicenter Observational Study.
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- January 1, 2020
- Completion date
- December 31, 2026
- Enrollment
- 73 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic urticaria (cu): chronic inducible urticaria (cindu) and chronic spontaneous urticaria (csu)